Your Dedicated Platform for T-Cell Engagers for Autoimmune Diseases to Foster New & Existing Relationships with Key Decision Makers Seeking Your Expertise
The T-Cell Engager for Autoimmune Disease Summit is designed to address the most critical challenges in developing safer, more effective, and clinically differentiated T-cell engagers for autoimmune disease.
As companies increasingly explore the potential of TCEs beyond oncology, the field is entering a new phase of development. Success in autoimmune disease requires more than adapting an oncology TCE platform, developers must account for different disease biology, heterogeneous patient populations, chronic treatment requirements, immune preservation, tissue-specific targets, and the need to achieve deep depletion without compromising long-term safety.
This shift is creating a growing need for trusted technology, platform, service, and strategic partners who understand both T-cell engager development and the unique requirements of autoimmune disease. Developed in close collaboration with autoimmune T-cell engager pioneers across discovery, translational, and clinical development, the summit focuses on advancing progress across key areas, including:
- Engineering next-generation T-cell engagers through CD3 tuning, conditional activation, trispecific designs, and immune synapse optimization to improve safety and reduce CRS
- Improving translational predictability through humanized models, patient-derived assays, biomarkers, immune profiling, and early clinical data
- Enabling precision target discovery beyond conventional B-cell depletion, including peptide-HLA targets, plasma cells, and autoreactive immune-cell populations
- Overcoming biological barriers including tissue penetration, T-cell exhaustion, target accessibility, and achieving deep and durable immune-cell depletion
- Supporting clinical development through dose optimization, PK/PD, biomarker strategies, CRS management, and long-term safety monitoring
- Differentiating autoimmune TCE programmes through regulatory, competitive, and commercial strategies as the therapeutic landscape becomes increasingly crowded
Partner with us in 2027 to position your organization at the forefront of this rapidly evolving field and connect directly with senior discovery, translational, preclinical, clinical, and business development leaders actively working to advance autoimmune TCE programmes. Whether you offer TCE platforms, novel targeting technologies, translational models, biomarker solutions, analytical capabilities, clinical development expertise, or strategic services, the summit provides an opportunity to demonstrate how your solutions can help companies overcome the unique challenges of translating TCEs into effective autoimmune therapies and build partnerships with the teams shaping the next generation of the field.
Why Partner with the T-Cell Engager for Autoimmune Disease Summit in 2027?
Showcase Your Technical Expertise
Demonstrate how your antibody or TCE-supporting platform addresses key challenges in autoimmune drug development, such as reducing immunotoxicity, boosting tissue selectivity, or refining target engagement.
Generate Qualified Leads Across Biotech & Pharma
Meet C-level, VP, and director-level stakeholders actively sourcing tools and collaborators for autoimmune-focused TCE discovery and development.
Highlight Your Role in Translational Advancement
Position your preclinical models, translational platforms, or bioanalytical services as essential for improving clinical safety and efficacy readouts in emerging autoimmune trials.
Shape Strategic Collaborations in a Rapidly Emerging Field
Be part of the conversations defining how TCEs will evolve in autoimmunity and partner with the innovators leading the charge beyond oncology.
Hear What Our Past Sponsors Have to Say
Smaller group, poster session with opportunity to network
COO, Structura Biotechnology
The caliber of the attendees was very high, and the meeting content was excellent
Project Leader, Evotec
Attending Companies Included